The aim of this study was to emphasise the role of radiotherapy and adequate surgery in the treatment of fibromatosis in patients presenting with newly diagnosed or recurrent disease and to analyse our treatment results over 15 years for this rare tumour type.

Materials and methods: Fifty-four patients with confirmed diagnosis of aggressive fibromatosis treated at King Faisal Specialist Hospital between 1990 and 2006 were identified from our local cancer registry.

Forty-seven MLN2238 concentration patients had surgery: complete resection (R0) in 20 patients, incomplete surgery (R1/2) in 27 patients, and seven patients had biopsy only. Forty-five patients were treated with radiotherapy: 38

patients were treated with postoperative radiotherapy, three patients were treated with preoperative radiotherapy and four patients had radiotherapy as the only treatment. The radiotherapy dose ranged between 45 and 60 Gy (median 50.4 Gy). Three patients did not receive any form of treatment apart from biopsy, but were still included in the final analysis.

Results: Fifty-two per cent (28/54 patients) of our patient population had tumour recurrence when first presented to King Faisal Specialist Hospital. The median age was 29.5 years (range 2-63 years). The most common site of involvement was the extremities (28 patients). Among the 54 patients (with primary

and recurrent presentation) there were 10 local recurrences, Crenolanib all of which were Mizoribine purchase within the original primary site. The 5-year progression-free survival and overall survival rates for the whole group were 75 and 95%, respectively. Univariate and multivariate Cox regression analysis showed that the depth of invasion significantly affected progression-free survival.

Conclusion: Aggressive fibromatosis is effectively treated with surgery and postoperative radiotherapy. Patients first presenting with tumour recurrence may still have local tumour control comparable with newly diagnosed patients. El-Haddad, M. et al. (2009). Clinical Oncology 21, 775-780 (C) 2009 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.”
“Yttrium silicate powders doped with Eu3+ and codoped with Eu3+ and Yb3+ were prepared by combustion synthesis. The x-ray powder diffraction data showed the presence of Y2SiO5 and Y2Si2O7 crystalline phases. Singly doped (1 wt%) sample illuminated with ultraviolet light (lambda = 256 nm) showed the characteristic red luminescence corresponding to D-5(0)–>F-7(J) transitions of Eu3+. The Judd-Ofelt intensity parameters were calculated from experimental data and the radiative and nonradiative relaxation rates were estimated.